Compare PRM & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRM | ACAD |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.4B |
| IPO Year | N/A | 2004 |
| Metric | PRM | ACAD |
|---|---|---|
| Price | $26.79 | $26.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | $28.00 | ★ $30.00 |
| AVG Volume (30 Days) | 747.9K | ★ 1.2M |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | 0.52 | ★ 1.54 |
| Revenue | $636,343,000.00 | ★ $1,047,118,000.00 |
| Revenue This Year | $15.59 | $15.16 |
| Revenue Next Year | $18.64 | $11.79 |
| P/E Ratio | $52.63 | ★ $17.43 |
| Revenue Growth | ★ 19.12 | 12.69 |
| 52 Week Low | $8.76 | $13.40 |
| 52 Week High | $29.88 | $28.35 |
| Indicator | PRM | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 47.07 |
| Support Level | $27.87 | $25.25 |
| Resistance Level | $29.48 | $27.81 |
| Average True Range (ATR) | 1.09 | 0.89 |
| MACD | -0.21 | -0.08 |
| Stochastic Oscillator | 1.03 | 38.28 |
Perimeter Solutions Inc is a solutions provider for the Fire Safety and Specialty Products industries. The Company's products and operations are managed and reported in two operating segments. Its Fire Safety segment provides fire retardants and firefighting foams, as well as specialized equipment and services typically offered in conjunction with the Company's retardant and foam products. The Specialty Products segment includes operations that develop, produce and market products for non-fire safety markets. Specialty Products segment is Phosphorus Pentasulfide (P2S5) based lubricant additives. P2S5 is also used in pesticide and mining chemicals applications, and emerging electric battery technologies.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.